Technical Analysis for RAPT - RAPT Therapeutics, Inc.

Grade Last Price % Change Price Change
F 1.05 -2.34% -0.03
RAPT closed unchanged on Wednesday, November 20, 2024, on 1.46 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
NR7 Range Contraction -2.34%
NR7-2 Range Contraction -2.34%
Narrow Range Bar Range Contraction -2.34%
Inside Day Range Contraction -2.34%
Wide Bands Range Expansion -2.34%
Oversold Stochastic Weakness -2.34%
New 52 Week Closing Low Bearish -2.34%
Calm After Storm Range Contraction -2.34%
NR7 Range Contraction -2.34%
NR7-2 Range Contraction -2.34%

   Recent Intraday Alerts

Alert Time
2x Volume Pace about 2 hours ago
1.5x Volume Pace about 2 hours ago
Down 5% about 2 hours ago
Fell Below Previous Day's Low about 2 hours ago
New 52 Week Low about 2 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

RAPT Therapeutics, Inc. Description

RAPT Therapeutics, Inc., a clinical stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company develops small molecules that are designed to modulate the critical immune responses underlying these diseases. Its lead oncology drug candidate is FLX475 for the treatment of a range of tumors; and RPT193, a CCR4 antagonist for allergic inflammatory disease. The company is also pursuing a range of targets, including general control nonderepressible and hematopoietic progenitor kinase for the treatment of cancer. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Disease Immunology Pharmacy Treatment Of Cancer Tumor Inflammatory Diseases Specialty Drugs Small Molecule Therapies Immune Response

Is RAPT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 27.35
52 Week Low 1.01
Average Volume 578,495
200-Day Moving Average 5.22
50-Day Moving Average 1.88
20-Day Moving Average 1.91
10-Day Moving Average 1.67
Average True Range 0.32
RSI (14) 32.89
ADX 29.18
+DI 19.45
-DI 31.49
Chandelier Exit (Long, 3 ATRs) 2.35
Chandelier Exit (Short, 3 ATRs) 1.98
Upper Bollinger Bands 3.10
Lower Bollinger Band 0.73
Percent B (%b) 0.14
BandWidth 123.67
MACD Line -0.23
MACD Signal Line -0.08
MACD Histogram -0.1481
Fundamentals Value
Market Cap 36.8 Million
Num Shares 34.4 Million
EPS -2.89
Price-to-Earnings (P/E) Ratio -0.37
Price-to-Sales 266.16
Price-to-Book 5.21
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.19
Resistance 3 (R3) 1.19 1.14 1.17
Resistance 2 (R2) 1.14 1.11 1.15 1.16
Resistance 1 (R1) 1.11 1.09 1.13 1.11 1.16
Pivot Point 1.06 1.06 1.07 1.07 1.06
Support 1 (S1) 1.03 1.03 1.05 1.03 0.98
Support 2 (S2) 0.98 1.01 0.99 0.98
Support 3 (S3) 0.95 0.98 0.97
Support 4 (S4) 0.95